Biocryst Pharmaceuticals (BCRX) Current Assets (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Current Assets came in at $373.6 million in Q1 2026, down 8.87% YoY from $410.0 million in Q1 2025, and down 7.6% on a QoQ basis from $404.3 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Current Assets (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Current Assets data on file, last reported at $373.6 million in Q1 2026.
- Quarterly Current Assets fell 8.87% year-over-year to $373.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.6 million (down 8.87% YoY) and the FY2025 annual result came in at $404.3 million, down 4.18% from the prior year.
- Current Assets fell to $373.6 million in Q1 2026, from $404.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $516.5 million in Q4 2022 to a low of $355.7 million in Q3 2025.
- A 5-year average of $449.1 million and a median of $447.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 101.39% — and 2024, when it slipped 28.88%.
- Tracing BCRX's Current Assets over 5 years: stood at $516.5 million in 2022, then slipped by 3.98% to $496.0 million in 2023, then slipped by 14.92% to $422.0 million in 2024, then fell by 4.18% to $404.3 million in 2025, then slipped by 7.6% to $373.6 million in 2026.
- The last three Current Assets figures came in at $373.6 million (Q1 2026), $404.3 million (Q4 2025), and $355.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.29 Bn | 43.33 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.57 Bn | 39.92 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 32.09 Bn | 30.41 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.32 Bn | 19.66 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | 3.22 Bn |
| 10 | Biocryst Pharmaceuticals | 2.48 Bn | 2.13 Bn | 214.41 Mn | 484.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 484.68 Mn |
| Mar 31, 2026 | 373.63 Mn |
| Dec 31, 2025 | 404.35 Mn |
| Sep 30, 2025 | 355.68 Mn |
| Jun 30, 2025 | 398.46 Mn |
| Mar 31, 2025 | 409.98 Mn |
| Dec 31, 2024 | 421.97 Mn |
| Sep 30, 2024 | 427.13 Mn |
| Jun 30, 2024 | 363.46 Mn |
| Mar 31, 2024 | 447.10 Mn |
| Dec 31, 2023 | 495.97 Mn |
| Sep 30, 2023 | 502.47 Mn |
| Jun 30, 2023 | 511.06 Mn |
| Mar 31, 2023 | 490.88 Mn |
| Dec 31, 2022 | 516.50 Mn |
| Sep 30, 2022 | 509.00 Mn |
| Jun 30, 2022 | 494.85 Mn |
| Mar 31, 2022 | 511.71 Mn |
| Dec 31, 2021 | 566.14 Mn |
| Sep 30, 2021 | 252.74 Mn |